Global Metabolism Drugs Market - 2023-2030

Market Overview

The Global Metabolism Drugs Market is expected to be valued at USD 16,094.36 million in 2022 and USD 26,369.52 million by 2030, with a CAGR of 6.5% throughout the forecast period.

Phenylketonuria, a disease in which the body is unable to break down the amino acid phenylalanine, is an illustration of a genetic metabolic disorder. Several more well-known metabolic diseases include type 1 diabetes, Gaucher's disease, maple syrup urine disease, cystinosis, Fabry disease, Hartnup disease, Hunter syndrome, Hurler syndrome, Von Gierke disease, and hereditary hemochromatosis.

By treating the underlying cause of the illness and employing medications to preserve optimal metabolic function, the treatment for metabolic disorders entails restoring metabolic balance.

Market Dynamics

Increasing Prevalence Of Metabolic Disorders

The increasing prevalence of metabolic disorders like phenylketonuria, citrullinemia, and maple syrup urine disease, as well as the high cost of treatments, have all contributed to the growth of the market for treatments for these disorders. Other factors driving this growth include rising disposable income in developing nations and the advancement of healthcare infrastructure.

The Rising Expense of Amino Acid Supplements

The demand for amino acids is predicted to increase among producers of animal feed in order to support animal development, reproduction, and other functions as well as to meet the animals' need for protein. Any amino acid deficit may cause animals to develop slowly, mature later, respond less quickly to immunological or metabolic stimuli, have low body weights, and have various health issues.

As a result, amino acids are becoming more crucial in the preparation of animal feed. The need for amino acids in the animal feed sector is also being driven by rising meat consumption and demand, as well as rising livestock output.

Side Effects Associated With Metabolism Drugs

Among the characteristics that have negative effects associated with drugs for metabolic disorders are increased heart rate and blood pressure, gastrointestinal issues, insomnia and sleep disturbance, dry mouth, etc.

For instance, Astellas Pharma, a pharmaceutical company based in Japan, in June 2022, announced that the USFDA put a clinical hold on FORTIS, which is currently undergoing a Phase 1/2 trial while evaluating the AT845 trial, which was an investigational AAV gene replacement therapy for adults with Late Onset Pompe Disease.

COVID-19 Impact Analysis

The supply and demand for medications that treat metabolic disorders have been affected by the COVID-19 pandemic. Since the COVID-19 vaccine is now the primary focus of research institutions and pharmaceutical corporations, sales of mass spectrometry, chromatography, and other metabolism-related research tools have somewhat decreased. The market for medications that affect metabolism is thus anticipated to see a significant drop in 2020.

Russia- Ukraine Conflcit Analysis

Russia's invasion of Ukraine affects millions of people worldwide. Drug developers are bound to face delays throughout the development process, a loss of business continuity, and the danger of non-compliance for pharmaceuticals already on the market.

The Russia-Ukraine conflict affected the investments in R&D due to which the import and exports of raw materials stopped and also investors were showing less interest during that period, which was affecting the metabolism drugs market.

Segment Analysis

The Diabetes Segment Will Dominate The Market In The Forecast Period.

The diabetes segment is estimated to hold about 35.6% of the global metabolism drugs market as plasma-free fatty acids (FFA) are more prevalent in diabetic individuals, diabetes may affect the way some medicines attach to plasma proteins, perhaps through glycosylation or protein displacement. However, albumin and 1-acid glycoprotein plasma concentrations wouldn't alter. Contrary to experimental research, the majority of medicines' metabolic clearance in people seems to be unaltered or slightly reduced in diabetes.

Geographical Analysis

North America is the Dominating Region During The Forecast Period.

Geographically, there are four regions that make up the worldwide market for metabolic disorders: North America, Europe, Asia Pacific, and the rest of the world (RoW). Due to the availability of cutting-edge technology and the greater penetration of diabetes care services throughout the region, North America is anticipated to lead the market throughout the projected period. North America is estimated to hold about 37.8% of the global metabolism drugs market.

Due to the high incidence of diabetes among the elderly population, the United States constituted a significant regional contributor. Over 25% of Americans with diabetes are 65 years of age or older, according to the American Diabetes Association. Over the projected period, Asia Pacific is anticipated to overtake North America as the region with the largest market for metabolic disorders. The region's healthcare reforms and an increase in the number of diabetics, particularly in India, are expected to drive the growth of the Asia Pacific market.

Competitive Landscape

The major global players include: Merck Sharp and Dohme Corp, Novartis AG, Amicus Therapeutics, AstraZeneca, Boehringer Ingelheim International GmbH, Takeda Pharmaceutical Company Limited, Sanofi, GlaxoSmithKline Plc, Horizon Therapeutics, and BioMarin Pharmaceuticals.

• Why Purchase the Report?
• To visualize the global metabolism drugs market segmentation based on the drug class, indication, distribution channels and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global metabolism drugs market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global metabolism drugs market report would provide approximately 92 tables, 108 figures and 195 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies